Login to Your Account



Ascletis’ $100M series B to advance HCV drugs to market in China

By Shannon Ellis
Staff Writer

Tuesday, January 3, 2017

SHANGHAI – The latest Chinese biopharma to receive a generous round of financing, Ascletis Pharmaceuticals Co. Ltd., of Hangzhou and Shaoxing, received $100 million from China-based venture capital firms.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription